The annual deductible for Medicare Part B rose $26 to $283 for 2026, and the standard monthly premium climbed $17.90 to $202.90, the Centers for Medicare & Medicaid Services confirmed in a fact sheet covering the program that pays for physician visits, outpatient care and durable medical equipment. Both figures took effect January 1 under a statutory formula tied to projected spending and utilization. CMS’s release ties much of that increase to one unusual driver: Medicare billing for wound-care products called skin substitutes grew nearly 40-fold in five years, and the agency’s own crackdown on that category already held the premium below what it otherwise would have been.
The Statutory Formula Behind the $283 Threshold
Part B’s deductible resets every calendar year and must be satisfied before Medicare’s standard 80 percent cost-sharing applies to most covered services, so the $26 increase means enrollees who see a doctor early in 2026 carry a larger share of the first bills before that split takes over. CMS describes the premium and deductible as set according to provisions of the Social Security Act, language that frames the annual jump as an automatic output of a formula rather than a discretionary decision. The same release shows the increase is not isolated to outpatient care: the Part A inpatient hospital deductible rose $60 to $1,736, and the standalone Part B immunosuppressive-drug-only premium, a narrower benefit for kidney-transplant recipients, is set at $121.60 for 2026.
The premium increase of $17.90 is proportionally larger than the deductible increase, moving the standard monthly rate from $185.00 to $202.90, a jump CMS attributes mainly to projected price changes and assumed utilization increases consistent with historical experience. That phrasing covers the routine mechanics of Part B financing, in which the trust fund’s projected spending for the coming year is divided among enrollees through the premium formula. What is less routine is that CMS chose to name a specific billing category large enough to move that formula on its own.
Free retirement updates: One number can cost or save hundreds a month in retirement. The free Retirement Shield newsletter surfaces the ones worth knowing. Sign up free.
A Nearly 40-Fold Billing Surge Behind Part of the Premium
Medicare Part B spending on skin substitutes, synthetic and biologic products applied to chronic wounds, rose from roughly $256 million in 2019 to more than $10 billion in 2024, growth CMS calls unprecedented and attributes largely to abusive pricing practices, including products billed at more than $2,000 per square centimeter with limited clinical evidence behind them. The agency’s Fraud Defense Operations Center stopped nearly $185 million in improper skin-substitute payments in 2025, including one case in which a single medical group billed $4.3 million for wound care purportedly provided to one beneficiary with no record of prior treatment.
To address the spending, CMS finalized a rule reclassifying skin substitutes as incident-to supplies rather than stand-alone biologicals starting in 2026, replacing a system in which each product carried its own billing code and price with a single payment rate of about $127.28. The agency projects the change will cut skin-substitute spending by nearly 90 percent and reduce gross Medicare fee-for-service spending on the category by $19.6 billion in 2026. In its Part B premium fact sheet, CMS states that without that rule, the standard monthly premium would have been about $11 more a month than the $202.90 figure that took effect.
That $11 gap is a rare instance of CMS publishing a counterfactual premium alongside the finalized one, effectively crediting a single regulatory change with holding 2026 Part B costs below where the underlying spending trend would otherwise have taken them. It means the $283 deductible and $202.90 premium, both framed as automatic formula outputs, actually embed a deliberate administrative intervention that accounts for roughly two-fifths of the premium’s total dollar increase.
Income Surcharges Push Some Premiums Past $689 a Month
Roughly 8 percent of Part B enrollees pay more than the standard premium under income-related monthly adjustment amounts, a surcharge structure in place since 2007 that scales with modified adjusted gross income. For 2026, an individual filer with income at or below $109,000, or a joint filer at or below $218,000, pays only the standard $202.90. Above those thresholds, the surcharge climbs in five steps, reaching $487.00 on top of the standard premium, a total monthly payment of $689.90, for individual filers with income of $500,000 or more, or joint filers at $750,000 or more.
The same income brackets apply to the narrower immunosuppressive-drug-only premium, where the top surcharge brings the monthly total to $608.10, and to beneficiaries who are married but file separate returns, who reach the maximum surcharge at a far lower income threshold, $391,000, than jointly filing couples. The surcharge schedule means two enrollees paying identical Part B deductibles can face monthly premiums more than three times apart, based on a prior tax return rather than on current medical use.
Hospital-Side Costs Climbed on the Same Formula, Without the Rule Change
The Part A side of the same CMS release shows deductibles and coinsurance rising in parallel with Part B, but without a comparable offsetting intervention. The inpatient hospital deductible, which covers the first 60 days of a covered hospital stay in a benefit period, rose from $1,676 to $1,736. Daily coinsurance for the 61st through 90th day of a hospitalization rose from $419 to $434, coinsurance for lifetime reserve days rose from $838 to $868, and the skilled-nursing-facility daily coinsurance for days 21 through 100 rose from $209.50 to $217. Because roughly 99 percent of beneficiaries qualify for premium-free Part A through their own or a spouse’s work history, the inpatient deductible, not a monthly premium, is the primary cost exposure tied to a hospital admission.
CMS has not identified a Part A equivalent to the skin-substitute billing surge, and its release offers no comparable counterfactual for what the inpatient deductible would have been absent some specific enforcement action. The contrast leaves the 2026 update as a test of a narrower question than the deductible increase itself: whether identifying and correcting a single high-growth billing category, as CMS did for skin substitutes on the Part B side, can meaningfully slow a cost formula that otherwise moves upward every year on projected spending and utilization alone.
This article was researched and drafted with the assistance of artificial intelligence.
More Financial Reading
